← All companies
Amylyx Pharmaceuticals, Inc.
AMLX - CIK 0001658551
Market cap$1.48 B
Rank#2327
SEC filings403
Amylyx Pharmaceuticals, Inc. trades as AMLX and has a market capitalization of $1.48 B, making it the #2327 largest US-listed company by market value. In its fiscal 2025 annual report the company posted revenue of $0.00, down 100.0% from the prior year and net income of -$144.74M. This page tracks Amylyx Pharmaceuticals, Inc. through 403 SEC filings, with financial statements and metrics updated as new reports are filed.
Key metrics
Revenue (latest FY)$0.00FY 2025
Net income (latest FY)-$144.74MFY 2025
Operating cash flow (latest FY)-$123.34MFY 2025
Total assets (latest FY)$332.64MFY 2025
Financial performance
Net profit margin expanded from -30853.0% to -345.4% over the same period - every figure below comes from the company's audited annual filings.
Key statistics
- Market cap
- $1.48 B
- Share price (derived)market cap / shares outstanding
- $13.35
- EPS (diluted)FY 2025
- $-1.53
- Shares outstandingas of 2026-04-27
- 0.11B
- Total equityas of 2026-03-31
- $273.16M
- Return on equity
- -53.0%
- Cash & equivalentsas of 2026-03-31
- $229.14M
- Current ratioas of 2026-03-31
- 17.85
Latest filings
| Filing | Type | Filed |
|---|---|---|
| Insider trade | 4 | 2026-05-26 |
| SCHEDULE 13G/A | - | 2026-05-15 |
| Quarterly report | 10-Q | 2026-05-07 |
| Major company event | 8-K | 2026-05-07 |
| Annual report to shareholders | ARS | 2026-04-23 |
| Proxy materials | DEFA14A | 2026-04-23 |
| Proxy statement | DEF 14A | 2026-04-23 |
| SCHEDULE 13G/A | - | 2026-03-26 |
Recent press releases
- Amylyx Pharmaceuticals Announces First Participant Dosed in ...2025-04-30
Amylyx Pharmaceuticals Announces First Participant Dosed in Pivotal Phase 3 LUCIDITY Trial of Avexitide in Post-Bariatric Hypoglycemia | Amylyx Pharmaceuticals, Inc.
- Amylyx Pharmaceuticals Reports Third Quarter 2024 Financial Results2024-11-07
Amylyx Pharmaceuticals Reports Third Quarter 2024 Financial Results | Amylyx Pharmaceuticals, Inc.
- Release Details - Investors2023-12-22
Amylyx Pharmaceuticals Announces First Participant Dosed in the Global Phase 3 ORION Study of AMX0035 in Progressive Supranuclear Palsy (PSP) | Amylyx Pharmaceuticals, Inc.
Similar companies
The largest companies sharing Amylyx Pharmaceuticals, Inc.'s SEC industry classification (pharmaceutical preparations).
Frequently asked questions
What is Amylyx Pharmaceuticals, Inc.'s market cap?
Amylyx Pharmaceuticals, Inc. (AMLX) has a market capitalization of $1.48 B as of 2026-06-10, ranking #2327 among US-listed companies.
How much revenue does Amylyx Pharmaceuticals, Inc. make?
Amylyx Pharmaceuticals, Inc. reported revenue of $0.00 for fiscal year 2025, a decrease of 100.0% year over year.
Is Amylyx Pharmaceuticals, Inc. profitable?
In its latest fiscal year Amylyx Pharmaceuticals, Inc. reported a net loss of $144.74M.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.